Cited by 995Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesPain Management and Opioid Use

The DOI matches its Crossref record; 36 of the 39 references it cites were found in a registry or an index.

Comparative effectiveness of different treatment pathways for opioid use disorder.

Open access

Wakeman, Sarah E., Larochelle, Marc R., Ameli, Omid, Chaisson, Christine E., McPheeters, Jeffrey Thomas, Crown, William H., Azocar, Francisca, Sanghavi, Darshak M.·2020·JAMA Network Open

DOI 10.1001/jamanetworkopen.2019.20622PMC PMC11143463

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking. Objective: To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence. Design, Setting, and Participants: This retrospective comparative effectiveness research study assessed deidentified claims from the OptumLabs Data Warehouse from individuals aged 16 years or older with OUD and commercial or Medicare Advantage coverage. Opioid use disorder was identified based on 1 or more inpatient or 2 or more outpatient claims for OUD diagnosis codes within 3 months of each other; 1 or more claims for OUD plus diagnosis codes for opioid-related overdose, injection-related infection, or inpatient detoxification or residential services; or MOUD claims between January 1, 2015, and September 30, 2017. Data analysis was performed from April 1, 2018, to June 30, 2019. Exposures: One of 6 mutually exclusive treatment pathways, including (1) no treatment, (2) inpatient detoxification or residential services, (3) intensive behavioral health, (4) buprenorphine or methadone, (5) naltrexone, and (6) nonintensive behavioral health. Main Outcomes and Measures: Opioid-related overdose or serious acute care use during 3 and 12 months after initial treatment. Results: A total of 40 885 individuals with OUD (mean [SD] age, 47.73 [17.25] years; 22 172 [54.2%] male; 30 332 [74.2%] white) were identified. For OUD treatment, 24 258 (59.3%) received nonintensive behavioral health, 6455 (15.8%) received inpatient detoxification or residential services, 5123 (12.5%) received MOUD treatment with buprenorphine or methadone, 1970 (4.8%) received intensive behavioral health, and 963 (2.4%) received MOUD treatment with naltrexone. During 3-month follow-up, 707 participants (1.7%) experienced an overdose, and 773 (1.9%) had serious opioid-related acute care use. Only treatment with buprenorphine or methadone was associated with a reduced risk of overdose during 3-month (adjusted hazard ratio [AHR], 0.24; 95% CI, 0.14-0.41) and 12-month (AHR, 0.41; 95% CI, 0.31-0.55) follow-up. Treatment with buprenorphine or methadone was also associated with reduction in serious opioid-related acute care use during 3-month (AHR, 0.68; 95% CI, 0.47-0.99) and 12-month (AHR, 0.74; 95% CI, 0.58-0.95) follow-up. Conclusions and Relevance: Treatment with buprenorphine or methadone was associated with reductions in overdose and serious opioid-related acute care use compared with other treatments. Strategies to address the underuse of MOUD are needed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamanetworkopen.2019.20622

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017
Scholl, L., Seth, P., Kariisa, M., Wilson, N. O., & Baldwin, G. T. (2018) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm675152e1 · Cited by 1,754
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076
Self-citation
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial
Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014
Zibbell, J. E., Asher, A. K., Patel, R. C., Kupronis, B. A., Iqbal, K., Ward, J. W., & Holtzman, D. J. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.304132 · Cited by 699
The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis
Ciccarone, D. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.01.010 · Cited by 677
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2-Phase Randomized Controlled Trial
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Medications for Opioid Use Disorder Save Lives
Mancher, M., & Leshner, A. (2019) · National Academies Press eBooks · doi:10.17226/25310 · Cited by 473

Flagged first, then by citations

Show all 39 references

3 of the 39 references couldn’t be matched to a known paper.

Sorted by citations

Items 601–700 of 995

Association Between Integrated Treatment Services and Access to Detoxification and MOUD Across US Treatment Facilities
Qeadan, F., Choudry, F., & Thornquist, R. (2026) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-026-10003-9 · Cited by 2
Glucagon-Like Peptide-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From Rats to Humans
Grigson, P. S., Bunce, S. C., Brick, T. R., Freet, C. S., Nyland, J. E., Kawasaki, S. S., Brandl, C. G., Shealy, E., & Huddleston, K. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.033 · Cited by 2
Recruitment into a Clinical Trial of People Living with Uncontrolled HIV Infection Who Inject Drugs: a Site Case Report from the CTN 67 CHOICES Study
Tookes, H. E., Ucha, J., Rodriguez, A. E., Suarez, E., Alonso, E., Metsch, L. R., Feaster, D. J., Bartholomew, T. S., Hoffman, K. A., & Korthuis, P. T. (2021) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-021-09771-3 · Cited by 2
A mixed-methods study of applied team integration for opioid use disorder treatment in rural settings
Campbell, M. J., Lucio, R., Cashwell, S. T., & Cowser, J. (2022) · Journal of Social Work Practice in the Addictions · doi:10.1080/1533256x.2022.2054155 · Cited by 2
“Helping the Helpers”—Making Access to Buprenorphine the New Standard of Care for Physicians in State Monitoring Programs
Dwarakanath, M., & Klipp, S. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001023 · Cited by 2
A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence
Greenwald, M. K., Ghosh, S., & Winston, J. R. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.101018 · Cited by 2
Racial inequities in opioid use disorder management: can the anesthesiologist improve outcomes?
Alalade, E., & Willer, B. L. (2022) · International Anesthesiology Clinics · doi:10.1097/aia.0000000000000383 · Cited by 2
Managing patients with comorbid opioid and alcohol use disorders
Gluck, R. L. (2023) · Current Psychiatry · doi:10.12788/cp.0327 · Cited by 2
Nonopioid Substance Use among Patients Who Recently Initiated Office-based Buprenorphine Treatment
Dugosh, K. L., Lent, M. R., Burkley, S. B., Millard, C., McKay, J. R., & Kampman, K. M. (2023) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001168 · Cited by 2
Buprenorphine and opioid analgesics: Dispensation and discontinuity among accidental overdose fatalities in the Indianapolis metropolitan area, 2016–2021
Victor, G. A., Ray, B. R., del Pozo, B., Jaffe, K., King, A., & Huynh, P. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209053 · Cited by 2
Outcomes Associated with Treatment with and Without Medications for Opioid Use Disorder
Mutter, R. L., Spencer, D. L., & McPheeters, J. (2023) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-023-09841-8 · Cited by 2
Self-citation
High-deductible Health Plans and Nonfatal Opioid Overdose
Eddelbuettel, J. C. P., Barry, C. L., Kennedy‐Hendricks, A., Busch, A. B., Hollander, M. A. G., Huskamp, H. A., Meiselbach, M. K., Schilling, C. J., Stuart, E. A., & Eisenberg, M. D. (2023) · Medical Care · doi:10.1097/mlr.0000000000001886 · Cited by 2
Problem-Solving Court Staff Preferences for Educational Videos About Medications for Opioid Use Disorder
Andraka‐Christou, B., Asi, Y., Totaram, R., & Matusow, H. (2022) · Substance Use & Misuse · doi:10.1080/10826084.2023.2236201 · Cited by 2
Contributions of a central registry to monitor methadone treatment through the HEALing Communities Study
Marks, K. R., Talbert, J., Hammerslag, L. R., Lofwall, M. R., Fanucchi, L. C., Broce, H., & WALSH, S. L. (2023) · Journal of Opioid Management · doi:10.5055/jom.2023.0801 · Cited by 2
Association of Opioid and Concurrent Benzodiazepine, Skeletal Muscle Relaxant, and Gabapentinoid Usage on Healthcare Expenditure and Resource Utilization: A Serial Cross-Sectional Study, 2009 to 2019
Sepassi, A., Li, M., Suh, K., Stottlemyer, B. A., & Bounthavong, M. (2024) · Substance Use & Addiction Journal · doi:10.1177/29767342241247372 · Cited by 2
Gut Microbiome-Mediated Mechanisms in Alleviating Opioid Addiction with Aqueous Extract of Anacyclus pyrethrum
Baslam, A., Kabdy, H., Chait, Y., Azraida, H., Yazouli, L. E., Aboufatima, R., Chait, A., & Baslam, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061152 · Cited by 3
Characterizing the Association Between Traumatic Brain Injury and Discontinuation of Medications for Opioid Use Disorder in a Commercially Insured Adult Population
Morgan, J. R., Reif, S., Stewart, M. T., Larochelle, M. R., & Adams, R. S. (2024) · Journal of Head Trauma Rehabilitation · doi:10.1097/htr.0000000000000964 · Cited by 2
Self-citation
Acute drug-use-related native tricuspid valve infective endocarditis: a non-surgical disease
El-Dalati, S. A., Alnabelsi, T. S., Gurley, J. C., Cremeans, K., Reda, H. K., London, T., Ogburn, E. A., & Sekela, M. E. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241267124 · Cited by 2
Emergency department management of opioid use disorder in pediatric patients
Schwarz, E. S., Dietrich, A. M., Sandelich, S., Hooley, G., Rose, E., Ruttan, T., Simon, E. L., Sulton, C., & Wall, J. (2024) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.13265 · Cited by 2
Client and program-level factors associated with planned use of medications for opioid use disorder in specialty substance use treatment programs: Evidence from linked administrative data and survey data
Feder, K. A., Li, Y., Burke, K. N., Byrne, L., Desai, I., Saloner, B. K., & Krawczyk, N. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209545 · Cited by 2
Randomised clinical trial of a 16 mg vs 24 mg maintenance daily dose of buprenorphine to increase retention in treatment among people with an opioid use disorder in Rhode Island: study protocol paper
Armeni, K., Chambers, L. C., Peachey, A. M., Berk, J., Langdon, K. J., Peterson, L., Beaudoin, F. L., & Wightman, R. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-085888 · Cited by 2
A Hospital-Based Intervention to Improve Access to Buprenorphine for Patients with Opioid Use Disorder
Fine, M., Hirt, L., Ormiston, C. K., Wang, L., Lee, T. G., & Herscher, M. (2024) · Substance Use & Addiction Journal · doi:10.1177/29767342241292416 · Cited by 2
Disparities in Receipt of Medications for Opioid Use Disorder Before and During the COVID-19 Pandemic in the US Veterans Health Administration
Sung, M., León, C., Reisman, J. I., Gordon, K. S., Kerns, R. D., Li, W., Liu, W., Mitra, A., Yu, H., & Becker, W. C. (2024) · Substance Use & Addiction Journal · doi:10.1177/29767342241293334 · Cited by 2
Understanding MAT access in the context of unused MAT capacity in the United States: when increasing rural MAT capacity is not enough
Mun, C. C., Zambrano, R., Tallman, E. F., Schuler, H., Bresani, E., & Meyers, K. (2024) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-024-00628-4 · Cited by 2
Examining how support persons’ buprenorphine attitudes and their communication about substance use impacts patient well-being
Choi, J., Burgette, L. F., Nameth, K., Watkins, K. E., & Osilla, K. C. (2025) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2024.2417820 · Cited by 2
Understanding engagement with an emergency department-based peer navigator intervention for opioid overdose prevention for a subset of patients experiencing homelessness
Routhier, G., Freeman, R., Welch, A. E., Chambless, D., Kepler, K. L., Jeffers, A., Silver, A., Gwadz, M. V., Cowan, E. A., Wittman, I., et al. (2025) · Journal of Social Distress and the Homeless · doi:10.1080/10530789.2025.2473760 · Cited by 2
Social networks illustrate harm reduction mechanisms in recovery homes
Sikora, A. J., Jason, L. A., Bobak, T. J., & Wu, D. (2025) · Journal of Prevention & Intervention in the Community · doi:10.1080/10852352.2025.2491864 · Cited by 2
Oral cavity cancer after sublingual buprenorphine use
Abruzzo, A. R., Harris, M. T. H., Sroussi, H., Suzuki, J., Kass, J. I., & Rettig, E. M. (2025) · Oral Oncology · doi:10.1016/j.oraloncology.2025.107573 · Cited by 2
Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review
Shirk, S. D., Ameral, V., Kraus, S. W., Houchins, J. R., Kelly, M. M., Pugh, K. E., Reilly, E. D., & Desai, N. (2021) · Journal of Dual Diagnosis · doi:10.1080/15504263.2021.1942380 · Cited by 2
Reprint of: Biotechnologies and the future of opioid addiction treatments
Wolfe, D., & Saucier, R. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103273 · Cited by 2
Bringing Primary Care to Opioid Treatment Programs
Olsen, Y. K., & Mason, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-80818-1_12 · Cited by 2
Breaking the cycle: A public-private partnership to combat the American opioid epidemic
Soled, D. R., Uppal, N., & Weiner, S. G. (2021) · Healthcare · doi:10.1016/j.hjdsi.2021.100592 · Cited by 2
Detoxification, 12-step meeting attendance, and non-fatal opioid overdoses among a suburban/exurban population with opioid use disorder
Clingan, S. E., Woodruff, S. I., Gaines, T. L., & Davidson, P. J. (2022) · Journal of Addictive Diseases · doi:10.1080/10550887.2022.2108287 · Cited by 2
The Role of Context in Integrating Buprenorphine into a Drop-In Center in Kampala, Uganda, Using the Consolidated Framework for Implementation Research
Dickson‐Gómez, J., Krechel, S., Katende, D., Johnston, B., Twaibu, W., Glasman, L. R., Ogwal, M., & Musinguzi, G. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191610382 · Cited by 2
County-level Factors and Treatment Access Among Insured Women With Opioid Use Disorder
Leech, A. A., McNeer, E. A., Stein, B. D., Richards, M. R., McElroy, T., Dupont, W. D., & Patrick, S. W. (2023) · Medical Care · doi:10.1097/mlr.0000000000001867 · Cited by 2
Low-dose buprenorphine initiation in the era of fentanyl and fentanyl analogs: A case series of outpatient inductions
Ahmed, S., Faruqui, Z., Poddar, K., Bhivandkar, S., & Suzuki, J. (2023) · Journal of Opioid Management · doi:10.5055/jom.0819 · Cited by 2
Nation’s Response to the Substance Use Crisis
Gupta, R. (2024) · North Carolina Medical Journal · doi:10.18043/001c.123261 · Cited by 2
Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder
Velez, F. F., Huang, D., Mody, L., & Malone, D. C. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2022.2016396 · Cited by 2
HIV and overdoses: diversifying therapies for opioid use disorder – Authors' reply
Hodder, S., Feinberg, J., Strathdee, S. A., SHOPTAW, S. J., Altice, F. L., Ortenzio, L., & Beyrer, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01221-6 · Cited by 2
Shifting Focus to Evidence-Based Management of Substance Use Disorders
Wakeman, S. E. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0150 · Cited by 2
Self-citation
Addressing Opioid Use Disorder in Primary Care: Revisiting Core Primary Care Principles to Confidently Initiate Treatment
Pytell, J. D., & Binswanger, I. A. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08727-5 · Cited by 2
“It's that longitudinal relationship that pays off”: A qualitative study of internal medicine residents’ perspectives on learning to prescribe buprenorphine
Logan, A. A., Jack, H. E., Darnton, J. B., & Klein, J. W. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1900990 · Cited by 1
Enhancing distress tolerance to uplift motivation in recovery: Results from an open development trial
Bhuptani, P. H., Block, A., Muñoz, P. J., Bello, M. S., Ramsey, S. E., Ranney, M. L., Carey, K. B., Rich, J. D., & Langdon, K. J. (2023) · Digital Health · doi:10.1177/20552076231158575 · Cited by 1
Patient-Centered Outcomes Associated With a Novel Office-Based Opioid Treatment Program in a District Health Department: Mixed Methods Pilot Study
Coles, T., Chen, H., Marais, A. C. D., Sachdeva, N., Bush, C. A., Harrison, L. M., & Guthrie, S. (2023) · JMIR Formative Research · doi:10.2196/40897 · Cited by 1
Access to Medications for Opioid Use Disorder During COVID-19: Retrospective Study of Commercially Insured Patients from 2019–2022
Rajagopal, S., Westra, J. R., Raji, M. A., Wilkes, D. M., & Kuo, Y. (2023) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2023.11.011 · Cited by 1
Universal Access to Opioid Agonist Therapy in Residential Treatment Settings: The Time Is Now
Muir, P., & Nolan, S. (2023) · The Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000187 · Cited by 1
“The Only Reason I Am Willing to Do It at All”: Evaluation of VA's SUpporting Primary care Providers in Opioid Risk reduction and Treatment (SUPPORT) Center
Williams, E. C., Frost, M. C., Danner, A. N., Lott, A. M. K., Achtmeyer, C. E., Hood, C., Malte, C. A., Saxon, A. J., & Hawkins, E. J. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001277 · Cited by 1
“I don't think that a medication is going to help someone long‐term stay off opioids”: Treatment and recovery beliefs of rural Vermont family members of people with opioid use disorder
Peasley‐Miklus, C., Shaw, J. G., Rosingana, K., Smith, M. L., Sigmon, S. C., Heil, S. H., Jewiss, J. L., Villanti, A. C., & Harder, V. S. (2024) · The Journal of Rural Health · doi:10.1111/jrh.12851 · Cited by 1
Exploring the Lived Experiences of Medication for Opioid use Disorder Treatment: A Qualitative Study among a Crowdsourced Convenience Sample
Victor, G. A., Kheibari, A., & Strickland, J. C. (2024) · Community Mental Health Journal · doi:10.1007/s10597-024-01345-9 · Cited by 1
Redefining low-threshold buprenorphine access in an integrated mobile clinic program: Factors associated with treatment retention
Harris, R., Stracker, N. H., Rice, M., Clair, A. S., Page, K. R., & Rosecrans, A. M. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209586 · Cited by 1
Telehealth and disparities in opioid use disorder treatment: Medicaid enrollees versus privately insured individuals
Allen, L., & Xu, M. (2024) · Health Services Research · doi:10.1111/1475-6773.14414 · Cited by 1
Patient acceptance of emergency department-initiated buprenorphine and reasons for declining
Jennings, L. K., Smith, A. B., Moreland, A. D., Ward, R. C., Gainey, S. S., Lane, S. M., Holodnik, O., Scarpino, K., Hartwell, K. J., Haynes, L. F., et al. (2025) · JEM Reports · doi:10.1016/j.jemrpt.2025.100141 · Cited by 1
Noninvasive Brain Stimulation for Opioid Use Disorder: An Update of the Literature
Blyth, S. H., Polick, C. S., Kim, L., Eason, S., Rubenstein, D., Thompson, S. C., Drummond, T., Ward, H. B., & Young, J. R. (2025) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-024-00293-8 · Cited by 1
“There’s always somebody that you can identify with”: a qualitative study of patient perspectives on buprenorphine group medical visits
Masyukova, M., Hayes, B. T., López‐Castro, T., & Fox, A. D. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00540-7 · Cited by 1
Examining associations between community drug-related exposure and receiving treatment among individuals with opioid use disorder (OUD) in the U.S.
Park, K., & Yang, T. (2025) · Journal of Substance Use · doi:10.1080/14659891.2025.2494527 · Cited by 1
Opioid use disorder Cascade of Care: defining a taxonomy for measurement
Henry, B. F., Krawczyk, N., Jordan, A. E., Cunningham, C. O., Lincourt, P., Hussain, S., Fotinos, C., & Williams, A. R. (2025) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2025.2494106 · Cited by 1
Use of harm reduction practices by state-licensed specialty substance use treatment programs
Desai, I., Burke, K., Li, Y., Ganetsky, V. S., Sugarman, O. K., Krawczyk, N., & Feder, K. A. (2025) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2025.209711 · Cited by 1
Facilitators and Challenges to Adoption of a Digital Health Tool for Opioid Use Disorder Treatment in Primary Care: Mixed Methods Study
Nieto, O., Rosen, A. D., Kalmin, M. M., Li, L., SHOPTAW, S. J., Jenkins, S. P., Ardestani, Z. Z., & Tulu, B. (2025) · Journal of Medical Internet Research · doi:10.2196/69953 · Cited by 1
The Impact of an Educational Intervention to Improve Emergency Medicine Resident Treatment of Individuals With Opioid Use Disorder
Hazekamp, C. S., Chang, B., Scoccimarro, A. D., West, J. R., & Sacco, D. L. (2025) · Journal of the American College of Emergency Physicians Open · doi:10.1016/j.acepjo.2025.100157 · Cited by 1
Experiences of Women Prescribed Methadone
Wimberly, A. S., Rawlett, K. E., Smith, J., & Murray-Browne, S. (2025) · Substance Use & Misuse · doi:10.1080/10826084.2025.2499604 · Cited by 1
Psychosocial Correlates of Insomnia Symptoms Among Women and Men Receiving Buprenorphine Treatment for Opioid Use Disorder
Chithranjan, S., Eglovitch, M., Marcus, M. M., Svikis, D. S., Alattar, M., & Martin, C. E. (2025) · NeuroSci · doi:10.3390/neurosci6020048 · Cited by 1
Predictors of Medicaid managed care plan performance on opioid use disorder treatment quality metrics
Stewart, M. T., Feltus, S. R., Andrews, C. M., Hodgkin, D., Parks, C. L., & Horgan, C. M. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112742 · Cited by 1
Mental health behaviors and suicide risk among White and Black adults with Opioid Use Disorder
Szlyk, H. S., Lew, D., Li, X., Filiatreau, L. M., Peoples, J. E., Kasson, E. M., & Cavazos‐Rehg, P. A. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118283 · Cited by 1
“Now It’s Up to Me to Take Advantage of the Shot”: Patient Perspectives on Hospital Initiation of Long-acting Injectable Buprenorphine
O'Conor, C. E., Armstrong, A., Sai, M., Farhi, S., Klug, E., Fitzgerald, R., & Shastry, S. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001529 · Cited by 1
Impact of Asynchronous Training on Student’s Confidence and Attitudes Regarding Patients With Opioid Use Disorders
Mullin, D. J., Cahill, A., Alford, D. P., Bergeron, N. P., Cushman, P. A., Gonzalez, G. M., Martin, S. A., Peterkin, A. F., Pothos, E. N., Pulaski, M., et al. (2025) · Substance Use & Addiction Journal · doi:10.1177/29767342251347358 · Cited by 1
Injectable buprenorphine during transition out of prison: A pilot partially randomized preference trial protocol
Berk, J., Cook, M., Martin, M. S., Lee, J. D., Koinis‐Mitchell, D., Brinkley‐Rubinstein, L., Drainoni, M., & Rich, J. D. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108004 · Cited by 1
Implementation of contingency management with women engaging in polysubstance use
Ward, K., Carrico, A. W., Vader, D. T., Moore, R. H., Amico, K. R., Groves, A. K., Bellamy, S. L., Sherman, S. G., Krakower, D., Mazzella, S., et al. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00590-x · Cited by 1
Delivering opioid use disorder treatment among American Indian and Alaska Native adults during the COVID-19 pandemic and beyond: Facilitators and barriers to care
Hirchak, K. A., Bajet, K., Richardson, M., Keyes, B., Shaffer, R., Oliver, K. A., Kropp, F. B., Campbell, A. N. C., & Venner, K. L. (2025) · Journal of Ethnicity in Substance Abuse · doi:10.1080/15332640.2025.2553322 · Cited by 1
Leveraging pharmacy partnerships and Grant funding to improve access to medications for opioid use disorder
Vasko, J. M., Orey, E. S., Wartman, C. C., Rowlett, J. K., Parker, J. D., Platt, D. M., & Schumacher, J. A. (2025) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2025.100653 · Cited by 1
Inpatient addiction care is associated with increased vaccinations, medication for opioid use disorder and naloxone prescribing among patients with infective endocarditis in a rural state
Farkas, E. J., MOLINA, V. V., Mohoney, B., Craig, W., Schaumberg, J., McAuliffe, A., & Thakarar, K. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00614-6 · Cited by 1
Potential health impacts of comprehensive access to opioid use disorder treatment in United States correctional facilities: A synthetic analysis
Smith, J. J., Noonan, M. E., Johnson, C. E., Humphreys, K. N., & Gupta, R. (2025) · Addiction · doi:10.1111/add.70170 · Cited by 1
Estimation and Comparison of Travel Burden to Outpatient, Opioid Treatment Program, and Residential Substance Use Disorder Treatment Programs
Bachhuber, M. A., Cunningham, C. O., Lincourt, P., & Jordan, A. E. (2025) · Substance Use & Addiction Journal · doi:10.1177/29767342251370825 · Cited by 1
Exploring medication for opioid use disorder and recovery housing in the United States
Hernandez, N., Santana, M., & Mendoza, N. S. (2025) · Journal of Social Work Practice in the Addictions · doi:10.1080/1533256x.2025.2578753 · Cited by 1
Willingness to receive medication for opioid use disorder (MOUD): A longitudinal analysis of social network support
Knudsen, H. K., Rockett, M., & Oser, C. B. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112966 · Cited by 1
Analysis of the costs and reach of transportation services to reduce barriers to opioid use disorder (OUD) treatment: evidence from the Kentucky HEALing Communities Study
Speer, D. D., Bush, J. L., Ekanayake, D. L., Nakayima, J., Goetz, M. M., Miles, J., Larimore, E., Knudsen, H. K., WALSH, S. L., & McCollister, K. E. (2026) · Addiction Science & Clinical Practice · doi:10.1186/s13722-026-00702-1 · Cited by 1
Strategies to Facilitate Interorganizational Collaboration in County-Level Opioid Overdose Prevention and Response: A Qualitative Analysis
Dickson‐Gómez, J., Krechel, S., Ohlrich, J., Hernandez-Meier, J., & Kostelac, C. A. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22121765 · Cited by 1
Methadone and morphine have equivalent analgesic but not reward potency in female mice
Shanmugam, A., Vanderhoof, S. O., Kelberman, M. A., Ferré, S., McCann, K. E., & Weinshenker, D. (2025) · Addiction Neuroscience · doi:10.1016/j.addicn.2025.100238 · Cited by 1
Hospital Care for Pregnant Persons With OUD Review
Park, J., Terplan, M., & Ratner, J. (2025) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2025.100117 · Cited by 1
Pathways to 7-day Extended-release Buprenorphine (CAM2038) Administration in Emergency Department and Hospitalized Patients
Logan, A. A., Sluser, J., & Martín, M. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001620 · Cited by 1
Expanding Access to Opioid Use Disorder Treatment: Low‐Threshold Buprenorphine Dispensing via an Interprofessional Mobile Medical Unit in Chicago
Elmes, A. T., Jarrett, J. B., Jimenez, A. D., Mayer, S., & Messmer, S. (2026) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70170 · Cited by 1
Retention on Buprenorphine for Opioid Use Disorder in Justice-Involved Individuals: A Retrospective Cohort Study
Yatsco, A. J., Vega, F. R., Cohen, A. S., Cárdenas-Turanzas, M., Langabeer, J. R., & Champagne‐Langabeer, T. (2026) · Behavioral Sciences · doi:10.3390/bs16010122 · Cited by 1
Management of Opioid Use Disorder
Messmer, S., Perri, M. M., & Davis, A. M. (2026) · JAMA · doi:10.1001/jama.2025.25464 · Cited by 1
External Validation of Epic’s Risk of Opioid Abuse and Overdose Model Among Primary Care Patients in Three Health Systems
Hooker, S. A., Rossom, R. C., Haapala, J. L., Crain, A. L., Miley, K. M., Olson, A. W., Kane, S. M., Christensen, K. S., O’Connor, P. J., Bart, G. B., et al. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10257-1 · Cited by 2
Statewide trends in access to medications for opioid use disorder (moud) among adolescents with opioid use disorders in Indiana
Gupta, S., Schwartz, K., Bell, L. A., Siegal, N., & Aalsma, M. C. (2026) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2026.100417 · Cited by 1
Algorithmic opacity in opioid risk scoring and the need for transparent AI regulation
Sherry Yun, W. A. N. G., Stofer, R., Yu, Q., Li, A., Mai, G., & Wang, H. (2026) · npj Digital Medicine · doi:10.1038/s41746-026-02491-y · Cited by 1
Buprenorphine utilization following removal of prior authorization requirements in the Kentucky Medicaid population
Miracle, D. K., Hammerslag, L. R., Slavova, S. S., Lofwall, M. R., WALSH, S. L., Talbert, J., & Freeman, P. R. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113105 · Cited by 1
Balancing transition and readmission: a comparative study of low-dose vs standard buprenorphine initiation for medically managed opioid withdrawal
Nichols, T., Lynch, S. T., Groenendaal, E., Towey, E., & Ferrando, S. J. (2026) · Journal of Addictive Diseases · doi:10.1080/10550887.2026.2625026 · Cited by 1
Relationship between extended-release buprenorphine adherence and reduced risk of return to use in patients with opioid use disorder: A retrospective claims data analysis
Jerry, M., Venkat, D., Flynn, C., Tran, A. T., Abdel-Sattar, M., Mullen, W., & Lane, C. (2026) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2026.100424 · Cited by 1
Longitudinal Patterns of Dental Health Care Utilization 18 Months Before and 36 Months After Initiation of Index Medications for Opioid Use Disorder
Roy, P. J., Yuan, N., Li, Y., Butler, A. M., Nickel, K. B., Gibson, G., Hubbard, C. C., Boyer, T. L., Suda, K. J., & Durkin, M. J. (2026) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001675 · Cited by 1
What are the true medical concerns facing unsheltered homeless adults?
Kuhn, R., Chien, J., Shannon, E. M., Saluja, S., Righi, G., Damra, M., King, C., Gelberg, L., & Henwood, B. F. (2026) · Health Affairs Scholar · doi:10.1093/haschl/qxag062 · Cited by 1
Treatment Outcomes in a Specialized Opioid Maintenance Program for Prescription Opioid Use Disorder in Israel
Mendelson, Z., Sason, A., Schreiber, S., Adelson, M., & Peles, E. (2026) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s584953 · Cited by 1
Treatment gaps for opioid use disorder among commercially insured US surgical patients, 2016–2022
Ervin-Sikhondze, B. A., Nguyen, T. D., Lagisetty, P., Hu, H. M., Waljee, J. F., Brummett, C. M., Li, Y., & Bicket, M. C. (2026) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2026-107625 · Cited by 1
Development, Feasibility, Acceptability, and Usability of an Artificial Intelligence–Powered Chatbot (Suzy) to Support Patients in Substance Use Disorder Recovery: Multiphase Study
Comulada, W. S., Swendeman, D. T., Ho, Y. X., Streck, J. M., Lewis, D.-M., Rezai, R., Warren, D., Pachas, G. N., Chandler, M., Jackson, J. L., et al. (2026) · JMIR Formative Research · doi:10.2196/84683 · Cited by 2
Influence of Attitudes on Recovery Residence Acceptance and Use of Medication for Opioid Use Disorder
Nichols, C. (2026) · Substance Use & Addiction Journal · doi:10.1177/29767342261426117 · Cited by 1
Adolescent Substance Use: Considerations for Pediatricians
Calihan, J. B., & Bagley, S. M. (2026) · American Academy of PediatricsItasca, IL eBooks · doi:10.1542/9781610028493-ch21 · Cited by 1
Self-reported differences between liquid and tablet methadone in persons with opioid use disorder
Dunn, K. E., McKendrick, G., Sklar, M., Davis, W., Sugrim, K., Myers, C., Finan, P. H., & Antoine, D. G. (2026) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2026.2654473 · Cited by 1
Criterion validity and divergent risk profiles of long-term opioid therapy across medicare and medicaid
Hurley, R. W., Guth, D., Hill, E., & Adams, M. C. B. (2026) · PLoS ONE · doi:10.1371/journal.pone.0347943 · Cited by 1
The Portuguese police experience with drug decriminalisation
Moniz, M., Ribeiro, B., Thompson, E., & del Pozo, B. (2026) · Policing & Society · doi:10.1080/10439463.2026.2674973 · Cited by 1
The comparative effects of prenatal exposure to methadone versus buprenorphine for opioid use disorder on neonatal outcomes: a systematic review and meta-analysis
Wilson, L. A., Tobias, S., Gandhi, P., Nosyk, B., Buxton, J. A., & Ti, L. (2026) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-026-09256-1 · Cited by 1
Social Determinants of Safety in a Rural Community
Gill, C. E. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009568555 · Cited by 1

Authors: Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M.
Affiliations: Harvard University (US)
Boston University (US)
Integrated Programs, OptumLabs Inc, Cambridge, Massachusetts
Optum (United States) (US)
Department of Research, OptumLabs, Cambridge, Massachusetts
Department of Research, Optum Behavioral Health, Cambridge, Massachusetts
UnitedHealth Group (United States) (US)
Corresponding author: Wakeman, Sarah E.
ORCID: Wakeman, Sarah E.
Larochelle, Marc R.
Ameli, Omid
Chaisson, Christine E.
Crown, William H.
Azocar, Francisca
Sanghavi, Darshak M.
Venue: JAMA Network Open
Publisher: American Medical Association (AMA)
Published: 2020-02-05
Volume: 3
Issue: 2
Pages: e1920622
ISSN: 2574-3805 (ISSN-L)
DOI: 10.1001/jamanetworkopen.2019.20622
PMC: PMC11143463
OpenAlex: W3005454586
Cited by: 995
References: 39
Citations by year: 2026: 137 · 2025: 170 · 2024: 192 · 2023: 161 · 2022: 158 · 2021: 128 · 2020: 49
FWCI: 92.82
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
Locations: JAMA Network Open (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Massachusetts General Hospital
School of Medicine, Boston University (1UL1TR001430)
Laura and John Arnold Foundation
Office of National Drug Control Policy (G1799ONDCP06B)
Hamilton Health Sciences Foundation
National Institutes of Health (UL1TR001430)
Centers for Disease Control and Prevention (U01CE002780)
U.S. Food and Drug Administration (HHSF223200910006I)
Substance Abuse and Mental Health Services Administration (1H79TI081442-01)
National Institute on Drug Abuse (K23DA042168, R01DA044526, UG1DA015831, G1799ONDCP06B)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords: opioid use disorder, medication-assisted treatment, buprenorphine, methadone, naltrexone, inpatient detoxification, residential treatment, opioid overdose, acute care utilization, treatment pathways, comparative effectiveness, real-world evidence, injection-related infections
MeSH terms: Adolescent, Adult, Analgesics, Opioid, Behavior Therapy, Buprenorphine, Female, Humans, Male, Methadone, Middle Aged, Opioid-Related Disorders, Retrospective Studies, United States, Proportional Hazards Models, Substance Abuse Treatment Centers, Treatment Outcome, Critical Pathways, Young Adult, Comparative Effectiveness Research, Opiate Substitution Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative effectiveness of different treatment pathways for opioid use disorder.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks